Bevacizumab is effective and useful for the treatment of a variety of tumors. Bevacizumab is a class of targeted drugs that can inhibit the activity of human vascular endothelial growth factor, and the target of action is VEGF, which mainly inhibits the development of metastatic foci, such as metastatic colon cancer, metastatic rectal cancer, etc., and it can also be used to reduce the generation of tumor microvessels, such as the treatment of non-small cell lung cancer. Bevacizumab mainly relies on the therapeutic effect or the occurrence of intolerance side effects to decide whether to discontinue. If serious adverse reactions occur, it is recommended to stop the drug immediately and go to the hospital for examination, and follow the doctor’s instructions for targeted treatment.